French Project to Tackle Antibiotic Resistance with Biotech and Economics
A team of French organizations led by the biotech firm Antabio has launched a €17M project to deploy therapeutic, diagnostic, and economic innovations in the battle against antibiotic resistance.
The project, dubbed ARPEGE, involves four partners covering a variety of disciplines: the antibiotics developer Antabio; the diagnostics heavyweight bioMérieux; the university hospital group Hospices Civils de Lyon (HCL) paired with the International Centre for Infectious Disease Research; and the Toulouse School of Economics (TSE). The total budget of the four-year project is expected to be €17M, with almost €9M already provided by the French government.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.